- Home
- TVTX vs IMCR Comparison
TVTX vs IMCR Comparison
Compare TVTX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- IMCR
- Stock Information
- Founded
- TVTX 2008
- IMCR 2008
- Country
- TVTX United States
- IMCR United Kingdom
- Employees
- TVTX N/A
- IMCR N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TVTX Health Care
- IMCR Health Care
- Exchange
- TVTX Nasdaq
- IMCR Nasdaq
- Market Cap
- TVTX 1.5B
- IMCR 1.5B
- IPO Year
- TVTX N/A
- IMCR 2021
- Fundamental
- Price
- TVTX $18.37
- IMCR $29.02
- Analyst Decision
- TVTX Buy
- IMCR Buy
- Analyst Count
- TVTX 12
- IMCR 13
- Target Price
- TVTX $24.58
- IMCR $65.18
- AVG Volume (30 Days)
- TVTX 1.2M
- IMCR 323.9K
- Earning Date
- TVTX 02-13-2025
- IMCR 02-26-2025
- Dividend Yield
- TVTX N/A
- IMCR N/A
- EPS Growth
- TVTX N/A
- IMCR N/A
- EPS
- TVTX N/A
- IMCR N/A
- Revenue
- TVTX $203,447,000.00
- IMCR $296,312,000.00
- Revenue This Year
- TVTX $62.38
- IMCR $28.91
- Revenue Next Year
- TVTX $57.65
- IMCR $12.65
- P/E Ratio
- TVTX N/A
- IMCR N/A
- Revenue Growth
- TVTX 57.08
- IMCR 25.09
- 52 Week Low
- TVTX $5.12
- IMCR $27.69
- 52 Week High
- TVTX $20.33
- IMCR $76.98
- Technical
- Relative Strength Index (RSI)
- TVTX 52.05
- IMCR 43.45
- Support Level
- TVTX $16.80
- IMCR $28.22
- Resistance Level
- TVTX $18.76
- IMCR $30.77
- Average True Range (ATR)
- TVTX 0.90
- IMCR 1.34
- MACD
- TVTX 0.02
- IMCR 0.03
- Stochastic Oscillator
- TVTX 61.57
- IMCR 23.32
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.